XORTX Targets FDA IND Submission for Gout Drug XRx-026, Eyeing $700M Market — XORTX Therapeutics Inc.

Event summary

XORTX plans to submit an Investigational New Drug (IND) application to the FDA for its XRx-026 gout program in Q4 2026.
The program targets a $700M+ U.S. gout market opportunity, leveraging its proprietary XORLO™ formulation of oxypurinol.
The submission follows positive prior clinical trial results and discussions with the FDA.
XORTX aims to file a New Drug Application (NDA) within approximately one year if the planned XRX-OXY-102 clinical trial is successful.

The big picture

XORTX's planned IND submission for XRx-026 is a critical step in addressing the unmet needs in the gout treatment market, which is expected to grow significantly over the next 25 years. The company's strategy to differentiate XORLO™ from existing therapies could position it favorably in a market where current options have limitations, including tolerability issues and cardiovascular risks. Success in this program could also set a precedent for XORTX's broader pipeline of kidney disease treatments.

What we're watching

Regulatory Approval: Whether the FDA will accept the IND submission and permit the planned clinical trial to proceed as outlined.
Market Differentiation: How XORLO™ will position itself against existing treatments like febuxostat and allopurinol, particularly given febuxostat's cardiovascular risk warning.
Execution Risk: The pace at which XORTX can secure sufficient funding and complete the XRX-OXY-102 clinical trial to meet its NDA submission target.